ID: ALA5201930

Max Phase: Preclinical

Molecular Formula: C24H28BrN9OS

Molecular Weight: 570.52

Associated Items:

Representations

Canonical SMILES:  CNC(=O)[C@]1(C)CC[C@@H](Nc2ncc3c(Br)nn(-c4ccc(-c5nnc(C)s5)c(CCN)c4)c3n2)C1

Standard InChI:  InChI=1S/C24H28BrN9OS/c1-13-31-32-21(36-13)17-5-4-16(10-14(17)7-9-26)34-20-18(19(25)33-34)12-28-23(30-20)29-15-6-8-24(2,11-15)22(35)27-3/h4-5,10,12,15H,6-9,11,26H2,1-3H3,(H,27,35)(H,28,29,30)/t15-,24-/m1/s1

Standard InChI Key:  SYLFBBHVQXOAKZ-OYLFLEFRSA-N

Associated Targets(Human)

Eukaryotic translation initiation factor 2-alpha kinase 4 471 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 570.52Molecular Weight (Monoisotopic): 569.1321AlogP: 3.62#Rotatable Bonds: 7
Polar Surface Area: 136.53Molecular Species: BASEHBA: 10HBD: 3
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 4#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 9.67CX LogP: 2.54CX LogD: 0.33
Aromatic Rings: 4Heavy Atoms: 36QED Weighted: 0.31Np Likeness Score: -0.82

References

1. Jackson JJ, Shibuya GM, Ravishankar B, Adusumilli L, Bradford D, Brockstedt DG, Bucher C, Bui M, Cho C, Colas C, Cutler G, Dukes A, Han X, Hu DX, Jacobson S, Kassner PD, Katibah GE, Ko MYM, Kolhatkar U, Leger PR, Ma A, Marshall L, Maung J, Ng AA, Okano A, Pookot D, Poon D, Ramana C, Reilly MK, Robles O, Schwarz JB, Shakhmin AA, Shunatona HP, Sreenivasan R, Tivitmahaisoon P, Xu M, Zaw T, Wustrow DJ, Zibinsky M..  (2022)  Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy.,  65  (19.0): [PMID:36127295] [10.1021/acs.jmedchem.2c00736]

Source